Advertisement
AMGN vs PFE
Which Stock Would AI Choose? Amgen (AMGN) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Amgen (AMGN) posted double-digit full-year revenue growth in 2025, driven by 14 blockbuster products, while Pfizer (PFE) reported a modest decline as fading COVID-19 sales weighed on results.
- AMGN faces a near-term patent headwind from Prolia/Xgeva biosimilars, whereas PFE is managing a broader loss-of-exclusivity period from 2026 through 2028.
- Both companies are pursuing obesity as a key growth catalyst — AMGN through its monthly-dose MariTide candidate and PFE through its roughly $7 billion Metsera acquisition.
- PFE trades at a notably lower forward price-to-earnings (P/E) multiple with a dividend yield approaching 7%, while AMGN commands a premium valuation on stronger recent momentum.
- Relative performance has diverged, with AMGN shares trending higher in recent months and PFE remaining range-bound below $30.
Introduction
Amgen and Pfizer are two of the largest names in global biopharmaceuticals, yet they currently present investors with sharply different profiles. Amgen is a biotechnology pioneer whose portfolio spans oncology, cardiometabolic disease, inflammation, and rare disease, while Pfizer is a diversified pharmaceutical giant navigating the aftermath of its pandemic-era COVID-19 revenue boom. This stock comparison is relevant for traders and investors weighing a growth-oriented, higher-multiple biotech against a value-oriented, high-yield pharmaceutical with a deeply discounted valuation. By examining business models, growth drivers, recent momentum, and market positioning, readers can better assess how these two equities compare in the current market environment.
AMGN Overview and Recent Performance
AMGN delivered strong operational performance in recent quarters, reporting 10% sales growth for 2025 and achieving blockbuster status — defined as $1 billion or more in annual sales — for 14 of its products. Growth has been led by fast-rising therapies such as Repatha (cholesterol), Evenity (osteoporosis), and Tezspire (asthma), each expanding by more than 30% year over year. Sentiment has also been supported by progress in its late-stage obesity candidate MariTide, which offers the prospect of monthly or even less frequent dosing. The main headwind is the erosion of Prolia and Xgeva sales following U.S. patent expirations, a factor management expects to pressure results in 2026. In recent market activity, AMGN shares have trended higher, with several analysts raising price targets and the company guiding to continued revenue growth.
PFE Overview and Recent Performance
PFE has spent recent quarters transitioning away from COVID-19 products as Comirnaty and Paxlovid sales have declined sharply. Full-year 2025 revenue dipped roughly 2% operationally, though the non-COVID portfolio grew about 9% operationally in the fourth quarter, led by Abrysvo, Eliquis, and the Vyndaqel family. Management has leaned heavily on cost discipline, targeting roughly $7.2 billion in net savings by 2027, and has pivoted aggressively into obesity through its acquisition of Metsera. The stock, however, remains below $30 and trades near a forward P/E of roughly 8.6x, reflecting investor caution about an upcoming loss-of-exclusivity period from 2026 through 2028. Recent market activity has kept PFE shares in a relatively narrow, range-bound pattern, with mixed analyst ratings and a dividend yield approaching 7%.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates the platform's best-performing AI trading bots for current market conditions. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of covered securities. Because every bot is built differently, only the most suitable performers for the prevailing environment earn a place in this curated section. The page highlights key statistics — including win rates, trade frequency, and returns — so traders can evaluate which bots align with their goals, whether they favor short-term momentum or longer-term positioning. Explore the Trending AI Robots to see which strategies are currently leading.
Head-to-Head Comparison
The two companies differ most clearly in their growth trajectory and valuation. AMGN is a biotechnology innovator with a concentrated pipeline and a high non-GAAP operating margin near 46%, but its premium valuation leaves less room for execution missteps. PFE is a diversified, dividend-focused pharmaceutical with a lower multiple and a heavier debt load following its Seagen acquisition, making it more sensitive to pipeline setbacks and patent expirations.
On growth drivers, AMGN's momentum is broad-based across oncology, cardiometabolic, and rare disease, while PFE's growth increasingly depends on successfully commercializing obesity assets from Metsera and offsetting a $1.5 billion revenue headwind from anticipated generic entry in 2026. On risk, AMGN faces concentrated erosion from Prolia/Xgeva biosimilars, whereas PFE faces a wider loss-of-exclusivity window and elevated leverage near its target. In terms of sentiment, AMGN has benefited from stronger recent price action, while PFE remains a "battleground" value stock with a high dividend yield but subdued technical momentum.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, and relative positioning, Tickeron's AI would likely favor AMGN over PFE in the current environment. AMGN's sustained double-digit revenue growth, expanding blockbuster portfolio, and constructive price trend present a more consistent upward pattern than PFE's range-bound movement and still-evolving obesity strategy. That said, the assessment is probabilistic rather than definitive: PFE's deep-value valuation and high dividend yield could appeal if its obesity pipeline delivers positive Phase 3 data or if its loss-of-exclusivity headwinds prove milder than expected. Traders should weigh AMGN's stronger recent momentum against PFE's income-oriented, turnaround-driven profile when evaluating market positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and PFE is a Buy.
AMGN in upward trend: 10-day moving average broke above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 45 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 32 of 47 cases over the following month. The odds of a continued upward trend are 68%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 148 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.555) is normal, around the industry mean (-1.376). P/E Ratio (28.731) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.039) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
PFE in +3.63% Uptrend, rising for three consecutive days on October 30, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 37 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 43%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 21 of 42 cases over the following month. The odds of a continued upward trend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 13 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 20 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.042) is normal, around the industry mean (-1.376). P/E Ratio (39.636) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.056) settles around the average of (0.039) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
AMGN | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 94 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | 100 | |
SMR RATING 1..100 | 15 | 83 | |
PRICE GROWTH RATING 1..100 | 6 | 20 | |
P/E GROWTH RATING 1..100 | 22 | 3 | |
SEASONALITY SCORE 1..100 | 23 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (79) in the Biotechnology industry is in the same range as PFE (96) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
AMGN's Profit vs Risk Rating (4) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for PFE (83) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (6) in the Biotechnology industry is in the same range as PFE (20) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (3) in the Pharmaceuticals Major industry is in the same range as AMGN (22) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 54% | 2 days ago 50% |
| Stochastic ODDS (%) | 2 days ago 48% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 43% |
| MACD ODDS (%) | 6 days ago 68% | 2 days ago 50% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 49% |
| Advances ODDS (%) | 2 days ago 62% | 2 days ago 54% |
| Declines ODDS (%) | 13 days ago 47% | 6 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 53% | 5 days ago 50% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 65% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +6.09% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.63% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.16%. For the same industry, the average monthly price growth was -2.39%, and the average quarterly price growth was +4.91%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.16% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +1.90% | ||
| BMY - PFE | 57% Loosely correlated | +1.78% | ||
| AMGN - PFE | 52% Loosely correlated | +1.15% | ||
| NVS - PFE | 49% Loosely correlated | -0.19% | ||
| BIIB - PFE | 48% Loosely correlated | +1.59% | ||
| SNY - PFE | 47% Loosely correlated | +2.81% | ||
More | ||||